Immunologic characterization of a Rhesus Macaque H1N1 challenge model for candidate influenza virus vaccine assessment

Clinical and Vaccine Immunology

Volumn 21, Issue 12, 2014, Pages 1668-1680

  Skinner, Jason A ^a   Zurawski, Sandra M ^a   Sugimoto, Chie ^b   Vinet Oliphant, Heather ^b   Vinod, Parvathi ^a   Xue, Yaming ^a   Russell Lodrigue, Kasi ^b   Albrecht, Randy A ^c   García Sastre, Adolfo ^c   Salazar, Andres M ^d   Roy, Chad J ^b   Kuroda, Marcelo J ^b   Oh, Sang Kon ^a   Zurawski, Gerard ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d Oncovir Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS ANTIBODY;

ANIMAL; BLOOD; HUMAN; IMMUNIZATION; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); ORTHOMYXOVIRIDAE INFECTIONS; RHESUS MONKEY; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MACACA MULATTA; ORTHOMYXOVIRIDAE INFECTIONS; VACCINATION;

EID: 84914113120     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00547-14     Document Type: Article

References (32)

1. Palese P, Wang TT. 2011. Why do influenza virus subtypes die out? A hypothesis. mBio 2(5):e00150-11. http://dx.doi.org/10.1128/mBio.00150-11.
2. Gerhard W. 2001. The role of the antibody response in influenza virus infection. Curr. Top. Microbiol. Immunol. 260:171-190.
3. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. 1982. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect. Immun. 36:1102-1108.
4. Kreijtz JH, Fouchier RA, Rimmelzwaan GF. 2011. Immune responses to influenza virus infection. Virus Res. 162:19-30. http://dx.doi.org/10.1016/j.virusres.2011.09.022.
5. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, Haynes L, Randall TD, Lund FE, Kaminski DA. 2011. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J. Virol. 85:5027-5035. http://dx.doi.org/10.1128/JVI.00150-11.
6. Boonnak K, Paskel M, Matsuoka Y, Vogel L, Subbarao K. 2012. Evaluation of replication, immunogenicity and protective efficacy of a live attenuated cold-adapted pandemic H1N1 influenza virus vaccine in nonhuman primates. Vaccine 30:5603-5610. http://dx.doi.org/10.1016/j.vaccine.2012.06.088.
7. Herfst S, van den Brand JM, Schrauwen EJ, de Wit E, Munster VJ, van Amerongen G, Linster M, Zaaraoui F, van Ijcken WF, Rimmelzwaan GF, Osterhaus AD, Fouchier RA, Andeweg AC, Kuiken T. 2010. Pandemic 2009 H1N1 influenza virus causes diffuse alveolar damage in cynomolgus macaques. Vet. Pathol. 47:1040-1047. http://dx.doi.org/10.1177/0300985810374836.
8. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, et al. 2009. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021-1025. http://dx.doi.org/10.1038/nature08260.
9. Safronetz D, Rockx B, Feldmann F, Belisle SE, Palermo RE, Brining D, Gardner D, Proll SC, Marzi A, Tsuda Y, Lacasse RA, Kercher L, York A, Korth MJ, Long D, Rosenke R, Shupert WL, Aranda CA, Mattoon JS, Kobasa D, Kobinger G, Li Y, Taubenberger JK, Richt JA, Parnell M, Ebihara H, Kawaoka Y, Katze MG, Feldmann H. 2011. Pandemic swine-origin H1N1 influenza A virus isolates show heterogeneous virulence in macaques. J. Virol. 85:1214-1223. http://dx.doi.org/10.1128/JVI.01848-10.
10. Josset L, Engelmann F, Haberthur K, Kelly S, Park B, Kawoaka Y, García-Sastre A, Katze MG, Messaoudi I. 2012. Increased viral loads and exacerbated innate host responses in aged macaques infected with the 2009 pandemic H1N1 influenza A virus. J. Virol. 86:11115-11127. http://dx.doi.org/10.1128/JVI.01571-12.
11. Go JT, Belisle SE, Tchitchek N, Tumpey TM, Ma W, Richt JA, Safronetz D, Feldmann H, Katze MG. 2012. 2009 pandemic H1N1 influenza virus elicits similar clinical course but differential host transcriptional response in mouse, macaque, and swine infection models. BMC Genomics 13:627. http://dx.doi.org/10.1186/1471-2164-13-627.
12. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, Zurawski S, Bosquet N, Palucka AK, Le Grand R, O'Garra A, Zurawski G, Banchereau J, Oh S. 2012. Targeting self-and foreign antigens to dendritic cells via DCASGPR generates IL-10-producing suppressive CD4 T cells. J. Exp. Med. 209:109-121. http://dx.doi.org/10.1084/jem.20110399.
13. Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, Agouna-Deciat O, Klucar P, Thompson-Snipes L, Zurawski S, Reiter Y, Palucka AK, Zurawski G, Banchereau J. 2010. Cross-priming CD8 T cells by targeting antigens to human dendritic cells through DCIR. Blood 116: 1685-1697. http://dx.doi.org/10.1182/blood-2010-01-264960.
14. Roy CJ, Adams AP, Wang E, Leal G, Seymour RL, Sivasubramani SK, Mega W, Frolov I, Didier PJ, Weaver SC. 2013. A chimeric Sindbisbased vaccine protects cynomolgus macaques against a lethal aerosol challenge of eastern equine encephalitis virus. Vaccine 31:1464-1470. http://dx.doi.org/10.1016/j.vaccine.2013.01.014.
15. Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R, Martinon F. 2012. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. Eur. J. Immunol. 42:2019-2030. http://dx.doi.org/10.1002/eji.201242478.
16. Flamar AL, Zurawski S, Scholz F, Gayet I, Ni L, Li XH, Klechevsky E, Quinn J, Oh S, Kaplan DH, Banchereau J, Zurawski G. 2012. Noncovalent assembly of anti-dendritic cell antibodies and antigens for evoking immune responses in vitro and in vivo. J. Immunol. 189:2645-2655. http://dx.doi.org/10.4049/jimmunol.1102390.
17. Flamar AL, Xue Y, Zurawski SM, Montes M, King B, Sloan L, Oh S, Banchereau J, Levy Y, Zurawski G. 2013. Targeting concatenated HIV antigens to human CD40 expands a broad repertoire of multifunctional CD4 and CD8 T cells. AIDS 27:2041-2051. http://dx.doi.org/10.1097/QAD.0b013e3283624305.
18. Friedberg JW, Kim H, McCauley M, Hessel EM, Sims P, Fisher DC, Nadler LM, Coffman RL, Freedman AS. 2005. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 105:489-495. http://dx.doi.org/10.1182/blood-2004-06-2156.
19. Rosenfeld MR, Chamberlain MC, Grossman SA, Peereboom DM, Lesser GJ, Batchelor TT, Desideri S, Salazar AM, Ye X. 2010. A multiinstitution phase II study of poly-ICLC and radiotherapy with concurrent and adjuvant temozolomide in adults with newly diagnosed glioblastoma. Neuro Oncol. 12:1071-1077. http://dx.doi.org/10.1093/neuonc/noq071.
20. Wang S, Taaffe J, Parker C, Solorzano A, Cao H, García-Sastre A, Lu S. 2006. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J. Virol. 80:11628-11637. http://dx.doi.org/10.1128/JVI.01065-06.
21. Pankla R, Buddhisa S, Berry M, Blankenship DM, Bancroft GJ, Banchereau J, Lertmemongkolchai G, Chaussabel D. 2009. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol. 10:R127. http://dx.doi.org/10.1186/gb-2009-10-11-r127.
22. Ivashkiv LB, Donlin LT. 2013. Regulation of type I interferon responses. Nat. Rev. Immunol. 14:36-49. http://dx.doi.org/10.1038/nri3581.
23. Woods CW, McClain MT, Chen M, Zaas AK, Nicholson BP, Varkey J, Veldman T, Kingsmore SF, Huang Y, Lambkin-Williams R, Gilbert AG, Hero AO, III, Ramsburg E, Glickman S, Lucas JE, Carin L, Ginsburg GS. 2013. A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2. PLoS One 8:e52198. http://dx.doi.org/10.1371/journal.pone.0052198.
24. Merekoulias G, Alexopoulos EC, Belezos T, Panagiotopoulou E, Jelastopulu DM. 2010. Lymphocyte to monocyte ratio as a screening tool for influenza. PLoS Curr. 2:RRN1154. http://dx.doi.org/10.1371/currents.RRN1154.
25. O'Donnell CD, Subbarao K. 2011. The contribution of animal models to the understanding of the host range and virulence of influenza A viruses. Microbes Infect. 13:502-515. http://dx.doi.org/10.1016/j.micinf.2011.01.014.
26. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, Lambkin-Williams R, Gilbert A, Oxford J, Nicholas B, Staples KJ, Dong T, Douek DC, McMichael AJ, Xu XN. 2012. Preexisting influenzaspecific CD4 T cells correlate with disease protection against influenza challenge in humans. Nat. Med. 18:274-280. http://dx.doi.org/10.1038/nm.2612.
27. Huang Y, Zaas AK, Rao A, Dobigeon N, Woolf PJ, Veldman T, Øien NC, McClain MT, Varkey JB, Nicholson B, Carin L, Kingsmore S, Woods CW, Ginsburg GS, Hero AO, III. 2011. Temporal dynamics of host molecular responses differentiate symptomatic and asymptomatic influenza A infection. PLoS Genet. 7:e1002234. http://dx.doi.org/10.1371/journal.pgen.1002234.
28. Hall CB, Douglas RG, Jr. 1975. Nosocomial influenza infection as a cause of intercurrent fevers in infants. Pediatrics 55:673-677.
29. Shinya K, Gao Y, Cilloniz C, Suzuki Y, Fujie M, Deng G, Zhu Q, Fan S, Makino A, Muramoto Y, Fukuyama S, Tamura D, Noda T, Eisfeld AJ, Katze MG, Chen H, Kawaoka Y. 2012. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque. J. Virol. 86:6055-6066. http://dx.doi.org/10.1128/JVI.00365-12.
30. Dinarello CA, Bernheim HA, Duff GW, Le HV, Nagabhushan TL, Hamilton NC, Coceani F. 1984. Mechanisms of fever induced by recombinant human interferon. J. Clin. Invest. 74:906-913. http://dx.doi.org/10.1172/JCI111508.
31. Ingimarsson S, Cantell K, Strander H. 1979. Side effects of long-term treatment with human leukocyte interferon. J. Infect. Dis. 140:560-563. http://dx.doi.org/10.1093/infdis/140.4.560.
32. Hashem AM, Gravel C, Chen Z, Yi Y, Tocchi M, Jaentschke B, Fan X, Li C, Rosu-Myles M, Pereboev A, He R, Wang J, Li X. 2014. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus. J. Immunol. 193:722-734. http://dx.doi.org/10.4049/jimmunol.1300093.